Home > Haematology > ASH 2020 > Lymphoma > CD58 aberrations limit durable responses to CD19 CAR T-cell therapy

CD58 aberrations limit durable responses to CD19 CAR T-cell therapy

Presented By
Dr Robbie Majzner, Stanford University, California, USA
Conference
ASH 2020
CD58 mutations have been reported in many cancers and are likely to play a role in immune evasion for chimaeric antigen receptor (CAR) T cells. CD58 status is found to be an important biomarker for durable response to CAR T cells in large B-cell lymphomas (LBCL). Dr Robbie Majzner (Stanford University, California, USA) modelled the biologic basis for this finding and generated CAR T cells capable of overcoming CD58 loss in B-cell malignancies [1]. CD19 CAR T cells have revolutionised the treatment of relapsed/refractory (R/R) LBCL, resulting in durable and complete responses in approximately 40-50% of patients [2]. “We wanted to focus on patients who do not obtain durable and complete responses, because the outcome of these patients is really poor, with a median overall survival (OS) of <200 days [3],” Dr Majzner explained [1]. “Because CAR T cells are able to induce long-term remission in patients, we feel t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on